News
-
-
-
COMMUNIQUÉ DE PRESSE
Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement
Tryp Therapeutics, Inc. and Exopharm Limited announce completion of acquisition deal through court-approved plan of arrangement. Shareholders to receive 3.616 Exopharm Shares for each Tryp Share held -
-
-
COMMUNIQUÉ DE PRESSE
Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
Tryp Therapeutics, Inc. announces shareholder approval and completion of plan of arrangement with Exopharm Limited. Anticipates trading on ASX as Tryptamine Therapeutics Limited (ticker symbol TYP) in May 2024 -
-
-
COMMUNIQUÉ DE PRESSE
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
Tryp Therapeutics announces securityholders' approval of Arrangement with Exopharm Limited CAN 163 765 991 at annual meeting. Closing expected in late March 2024 -
COMMUNIQUÉ DE PRESSE
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Tryp Therapeutics, Inc. obtains interim court order for proposed arrangement with Exopharm Limited ACN 163 765 991. Meeting scheduled for March 8, 2024, in Toronto, Ontario, to vote on the arrangement resolution
